Literature DB >> 3953564

Immunoregulatory abnormalities in myelodysplastic disorders.

M A Baumann, T J Milson, C W Patrick, J A Libnoch, R H Keller.   

Abstract

Immunoregulation was assessed in a group of patients with myelodysplasia (MDS) by flow cytometric analysis of peripheral blood lymphocyte subsets and in vitro studies of mitogen-stimulated T-lymphocyte blastogenesis. Mitogenesis was significantly depressed in MDS patients compared to controls (p less than .001) and a similar defect was found in a small group of patients with untreated acute nonlymphocytic leukemia (ANLL) (p less than .005). The impaired mitogenic response ability of T-cells in these patients did not appear to be the result of alteration in lymphocyte subpopulation ratios. The observed defect might result from defective cooperation between T-lymphocytes and abnormal myeloid elements. Alternatively, the lymphocytes themselves could be derived from the abnormal clone and thus be functionally abnormal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3953564     DOI: 10.1002/ajh.2830220104

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population.

Authors:  Dragomir Marisavljević; Nada Kraguljac; Zoran Rolović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.

Authors:  O Iwase; S Aizawa; Y Kuriyama; M Yaguchi; M Nakano; K Toyama
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

4.  Bone marrow lymphocyte subsets in myelodysplastic syndromes.

Authors:  W Hilbe; W Eisterer; C Schmid; I Starz; H Silly; C Duba; C Ludescher; J Thaler
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

5.  Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.

Authors:  G Seipelt; A Ganser; H Duranceyk; A Maurer; O G Ottmann; D Hoelzer
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.